Skip to main content
SpringerLink
Log in

Acquisition of an Antiestrogen-Resistant Phenotype in Breast Cancer: Role of Cellular and Molecular Mechanisms

  • Chapter
Drug Resistance

Part of the book series: Cancer Treatment and Research ((CTAR,volume 87))

Abstract

It is estimated that almost 11% of all women living to age 80 will develop breast cancer [1]. The annual worldwide incidence of breast cancer is estimated to be one million by the year 2000 [1]. The factors responsible for the genesis of breast cancer remain unclear, but estrogens have been strongly implicated [2]. Estrogens may function as carcinogens and/or cocarcinogens [2,3], but it is their role as promoters of the growth of estrogen-dependent and estrogen-responsive tumors through activation of their nuclear receptors [2] that has provided a rationale for the design of therapeutic strategies, that is, antiestrogens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Miller AB, Bulbrook RD (1986) UICC multidisciplinary project on breast cancer: The epidemiology, aetiology and prevention of breast cancer. Int J Cancer 37:173–177.

    PubMed  CAS  Google Scholar 

  2. Clarke R, Dickson RB, Lippman ME (1992) Hormonal aspects of breast cancer: Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 12:1–23.

    PubMed  CAS  Google Scholar 

  3. Li JJ, Mueller GC, Sekely LI (1991) Workshop report from the Division of Cancer Etiology, National Cancer Institute, National Institutes of Health. Current Perspectives and Future Trends in Hormonal Carcinogenesis. Cancer Res 51:3626–3629.

    PubMed  CAS  Google Scholar 

  4. Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: Suggestions from a new method of treatment, with ilustrative cases. Lancet 2:104–107.

    Google Scholar 

  5. Kistner RW, Smith OW (1960) Observations on the use of a non-steroidal estrogen antagonist: Mer-25. Surg Forum 10:725–729.

    PubMed  CAS  Google Scholar 

  6. Herbst AL, Griffiths CT, Kistner RW (1964) Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer Chemother Rep 443:39–41.

    Google Scholar 

  7. Cole MP, Jones CTA, Todd IDH (1971) A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 25:270–275.

    PubMed  CAS  Google Scholar 

  8. Litherland S, Jackson IM (1988) Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 15:183–194.

    PubMed  CAS  Google Scholar 

  9. Magdelenat H, Pouillart P (1988) Steroid hormone receptors in breast cancer. In PJ Sheridan, K Blum, MC Trachtenberg, eds. Steroid Receptors and Disease: Cancer Autoimmune, Bone and Circulatory Disorders. New York: Marcel Dekker, pp 435–465.

    Google Scholar 

  10. McGuire WL, Clark GM (1983) The prognostic role of progesterone receptor in human breast cancer. Semin Oncol 10:2–6.

    PubMed  CAS  Google Scholar 

  11. NATO (1985) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Lancet 2:836–839.

    Google Scholar 

  12. Committee (1987) BCT Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1:171–175.

    Google Scholar 

  13. Henderson IC, Shapiro CL (1991) Adjuvant chemotherapy: An overview. In T Powles, IE Smith, eds. Medical Management of Breast Cancer. London: Dunitz, pp 197–215.

    Google Scholar 

  14. Clarke R, Dickson RB, Brünner N (1990) The process of malignant progression in human breast cancer. Ann Oncol 1:401–407.

    PubMed  CAS  Google Scholar 

  15. Clarke R, Thompson EW, Leonessa F, Lippman J, McGarvey M, Brünner N (1993) Hormone resistance, invasiveness and metastatic potential in human breast cancer. Breast Cancer Res Treat 24:227–239.

    PubMed  CAS  Google Scholar 

  16. Clarke R, Leonessa F (1994) Cytotoxic drugs and hormones in breast cancer: Interactions at the cellular level. In RB Dickson, ME Lippman, eds. Drug and Hormonal Resistance in Breast Cancer: Cellular and Molecular Mechanisms. Chichester, UK: Ellis Horwood, pp 407–432.

    Google Scholar 

  17. Leonessa F, Boulay V, Wright A, Thompson EW, Brünner N, Clarke R (1991) The biology of breast tumor progression: Acquisition of hormone-independence and resistance to cytotoxic drugs. Acta Oncol 31:115–123.

    Google Scholar 

  18. Barsky SH, Togo S, Garbisa S, Liotta LA (1994) Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet 1:296–297.

    Google Scholar 

  19. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152–158.

    PubMed  CAS  Google Scholar 

  20. Zyad A, Bernard J, Clarke R, Tursz T, Brockhaus M, Chouaib S (1994) Human breast cancer cross-resistance to TNF and Adriamycin: Relationship to MDR1, MnSOD and TNF gene expression. Cancer Res 54:825–831.

    PubMed  CAS  Google Scholar 

  21. Morrow CS, Chiu J, Cowan KH (1992) Posttranscriptional control of glutathione S-transferase pi gene expression in human breast cancer cells. J Biol Chem 267:10544–10550.

    PubMed  CAS  Google Scholar 

  22. Fuqua SAW, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK (1994) Heat shock proteins and drug resistance. Breast Cancer Res Treat 32:67–71.

    PubMed  CAS  Google Scholar 

  23. Tuccari G, Rizzo A, Giuffre G, Barresi G (1993) Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: Correlation with clinico-pathological features. Virchows Arch A Pathol Anat Histopathol 423:51–55.

    PubMed  CAS  Google Scholar 

  24. Hahnel R, Twaddle E, Ratajczak T (1973) The influence of synthetic anti-estrogens on the binding of tritiated estradiol-17β by cytosols of human uterus and human breast carcinoma. J Steroid Biochem 4:687–695.

    PubMed  CAS  Google Scholar 

  25. Clarke R, Lippman ME (1992) Antiestrogens resistance: Mechanisms and reversal. In BA Teicher, ed. Drug Resistance in Oncology. New York: Marcel Dekker, pp 501–536.

    Google Scholar 

  26. Nardulli AM, Green GL, O’Malley BW, Katzenellenbogen BS (1988) Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: Analysis of estrogen’s effect on progesterone receptor synthesis and degradation. Endocrinology 122:935–944.

    PubMed  CAS  Google Scholar 

  27. Lam H-YP (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Comm 118:27–32.

    PubMed  CAS  Google Scholar 

  28. Clarke R, van den Berg HW, Murphy RF (1990) Tamoxifen and 17β-estradiol reduce the membrane fluidity of human breast cancer cells. J Natl Cancer Inst 82:1702–1705.

    PubMed  CAS  Google Scholar 

  29. Pasqualini JR, Nguyen B-L (1991) Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. independent human breast cancer cell lines. Breast Cancer Res Treat 18:93–98.

    PubMed  CAS  Google Scholar 

  30. Ravdin PM, Fritz NF, Tormey DC, Jordan VC (1988) Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026–1029.

    PubMed  CAS  Google Scholar 

  31. Clarke R, Brünner N, Thompson EW, Glanz P, Katz D, Dickson RB, Lippman ME (1989) The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J Endocrinol 122:331–340.

    PubMed  CAS  Google Scholar 

  32. Plotkin D, Lechner JJ, Jung WE, Rosen PJ (1978) Tamoxifen flare in advanced breast cancer. JAMA 240:2644–2646.

    PubMed  CAS  Google Scholar 

  33. Clarysse A (1985) Hormone-induced tumor flare. Eur J Cancer Clin Oncol 21:545–547.

    PubMed  CAS  Google Scholar 

  34. Etienne MC, Milano G, Fischcel JL, Frenay M, Francois E, Formento JL, Gioanni J, Namer M (1989) Tamoxifen metabolism: Pharmacokinetic and in vitro study. Br J Cancer 60:30–35.

    PubMed  CAS  Google Scholar 

  35. Buckely MM-T, Goa KL (1989) Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37:451–490.

    Google Scholar 

  36. Katzenellenbogen BS, Ferguson ER (1975) Antiestrogen action in the uterus: Biological ineffectiveness of nuclear bound estradiol after antiestrogen. Endocrinology 97:1–12.

    PubMed  CAS  Google Scholar 

  37. Ferrazzi E, Cartei G, Matarazzo R (1977) Oestrogen-like effect of tamoxifen on vaginal epithelium. Lancet 1:1351–1352.

    CAS  Google Scholar 

  38. Gusberg SB (1990) Tamoxifen for breast cancer: Associated endometrial cancer. Cancer 65:1463–1464.

    PubMed  CAS  Google Scholar 

  39. Pasqualini JR, Sumida C, Giambiagi N (1988) Pharmacodynamic and biological effects of antiestrogens in different models. J Steroid Biochem 31:613–643.

    PubMed  CAS  Google Scholar 

  40. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS (1982) Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16:1–13.

    PubMed  CAS  Google Scholar 

  41. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC (1991) Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to breast cancer patients. Drug Metab Dispos Biol Fate Chem 19:36–43.

    PubMed  CAS  Google Scholar 

  42. Terenius L (1970) Two modes of interactions between oestrogen and anti-oestrogen. Acta Endocrinol 64:47–58.

    PubMed  CAS  Google Scholar 

  43. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB (1989) ICI 164,384: A pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 49:6929–6934.

    PubMed  CAS  Google Scholar 

  44. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873.

    PubMed  CAS  Google Scholar 

  45. Clarke R, Brünner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME, Dickson RB (1989) Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc Natl Acad Sci USA 86:3649–3653.

    PubMed  CAS  Google Scholar 

  46. Seibert K, Shafie SM, Triche TJ, Whang-Peng JJ, O’Brien SJ, Toney JH, Huff KK, Lippman ME (1983) Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res 43:2223–2239.

    PubMed  CAS  Google Scholar 

  47. Brünner N, Svenstrup B, Spang-Thompsen M, Bennet P, Nielsen A, Nielsen JJ (1986) Serum steroid levels in intact and endocrine ablated Balb\c nude mice and their intact litter mates. J Steroid Biochem 25:429–432.

    PubMed  Google Scholar 

  48. Brünner N, Boulay V, Fojo A, Freter C, Lippman ME, Clarke R (1993) Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53:283–290.

    PubMed  Google Scholar 

  49. Coopman P, Garcia M, Brünner N, Derocq D, Clarke R, Rochefort H (1994) Antiproliferative and antiestrogenic effects of ICI 164,384 in 4-OH-Tamoxifen-resistant human breast cancer cells. Int J Cancer 56:295–300.

    PubMed  CAS  Google Scholar 

  50. Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R (1993) MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53:3229–3232.

    PubMed  Google Scholar 

  51. Kemp JV, Adam HK, Wakeling AE, Slater R (1983) Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 32:2045–2052.

    PubMed  CAS  Google Scholar 

  52. Jordan VC, Bain RR, Brown RR, Gordon B, Santos MA (1983) Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 43:1446–1450.

    PubMed  CAS  Google Scholar 

  53. Katzenellenbogen BS, Norman MJ, Eckert RL, Pelyz SW, Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112–119.

    PubMed  CAS  Google Scholar 

  54. Jordan VC, Robinson SP (1987) Species-specific pharmacology of antiestrogens: Role of metabolism. Fed Proc 46:1870–1874.

    PubMed  CAS  Google Scholar 

  55. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW (1992) Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10:990–994.

    PubMed  CAS  Google Scholar 

  56. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M (1991) Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477–1482.

    PubMed  CAS  Google Scholar 

  57. Gottardis MM, Wagner RJ, Borden EC, Jordan CV (1989) Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49:4765–4769.

    PubMed  CAS  Google Scholar 

  58. Osborne CK, Coronado EB, Robinson JP (1987) Human breast cancer in athymic nude mice: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189–1196.

    PubMed  CAS  Google Scholar 

  59. Jiang S-Y, Jordan VC (1992) Growth regulation of estrogen receptor negative breast cancer cells transfected with estrogen receptor cDNAs. J Natl Cancer Inst 84:580–591.

    PubMed  CAS  Google Scholar 

  60. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel JA, Lippman ME, Dickson RB, Kern FG (1993) Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoifen-treated athymic nude mice. Cancer Res 53:2168–2177.

    PubMed  CAS  Google Scholar 

  61. Wolf DM, Langan-Fahey SM, Parker CP, McCague R, Jordan VC (1993) Investigation of the mechanism of tamoxifen stimulated breast tumor growth; non-isomerizable analogues of tamoxifen and its metabolites. J Natl Cancer Inst 85:806–812.

    PubMed  CAS  Google Scholar 

  62. Belani CP, Pearl P, Whitley NO, Aisner J (1989) Tomoxifen withdrawal response: report of a case. Arch Intern Med 149:449–450.

    PubMed  CAS  Google Scholar 

  63. McIntosh IH, Thynne GS (1977) Tumor stimulation by anti-oestrogens. Br J Surg 64:900–901.

    PubMed  CAS  Google Scholar 

  64. Stein W, Hortobagyi GN, Blumenschein GR (1983) Response of metastatic breast cancer to famoxifen withdrawal: Report of a case. J Surg Oncol 22:45–46.

    PubMed  Google Scholar 

  65. Allegra CJ (1990) Antifolates. In BA Chabner, JM Collins, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia: JB Lippincott, pp 110–153.

    Google Scholar 

  66. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486–4490.

    PubMed  CAS  Google Scholar 

  67. Johnston SRD, Haynes BP, Smith IE, Jarman M, Sacks NPM, Ebbs SR, Dowsett M (1993) Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342:1521–1522.

    PubMed  CAS  Google Scholar 

  68. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R (1994) The effect of tamoxifen on the multidrug resistant phenotype in human breast cancer cells: Isobologram, drug accumulation and gp-170 binding studies. Cancer Res 54:441–447.

    PubMed  CAS  Google Scholar 

  69. Ramu A, Glaubiger D, Fuks Z (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44:4392–4395.

    PubMed  CAS  Google Scholar 

  70. Keen JC, Miller EP, Bellamy C, Dixon JM, Miller WR (1994) P-glycoprotein and resistance to tamoxifen. Lancet 343:1047–1048.

    PubMed  CAS  Google Scholar 

  71. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, Dickson RB (1992) Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 84:1506–1512.

    PubMed  CAS  Google Scholar 

  72. Szamel I, Hindy I, Vincze B, Eckhardt S, Kangas L, Hajba A (1994) Influence of toremifene on the endocrine regulation of breast cancer patients. Eur J Cancer 30A:154–158.

    PubMed  CAS  Google Scholar 

  73. Brodie AMH, Santen RJ (1985) Aromatase in breast cancer and the role of aminogluthemide and other aromatase inhibitors. CRC Crit Rev Oncol Hematol 5:361–396.

    Google Scholar 

  74. Reed MJ, Owen AM, Lai LC, Coldham NG, Ghilchik MW, Shaikh NA, James VHT (1989) In situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione. Int J Cancer 44:233–237.

    PubMed  CAS  Google Scholar 

  75. Hardy JR, Judson IR, Sinnett HD, Ashley SE, Coombes RC, Ellin CL (1990) Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Eur J Cancer 26:824–827.

    PubMed  CAS  Google Scholar 

  76. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284–1291.

    PubMed  CAS  Google Scholar 

  77. Patterson JS, Edwards DG, Battersby LA (1981) A review of the international clinical experience with tamoxifen. Jpn J Cancer Clin (Suppl):157–183.

    Google Scholar 

  78. Vuletic L, Bugarski M, Boberic J, Milosauljevic A, Naumovic P (1981) Treatment of advanced breast cancer with tamoxifen: A pilot study. Rev Endoc Related Cancer 9:533–545.

    Google Scholar 

  79. Van Netten JP, Algard FT, Coy P (1985) Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast tumors. Cancer 56:2019–2024.

    PubMed  Google Scholar 

  80. Van Netten JP, Armstrong JB, Carlyle SS, Goodchild NL, Thormton IG, Brigden ML, Coy P, Fletcher C (1988) Estrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers. Eur J Cancer Clin Oncol 24:1885–1889.

    PubMed  Google Scholar 

  81. Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63:1727–1733.

    PubMed  CAS  Google Scholar 

  82. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237–246.

    PubMed  CAS  Google Scholar 

  83. Johnston SRD, Saccanti-Jotti G, Smith IE, Newby J, Dowsett M (1995) Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer. Endocr Related Cancer 2:105–110.

    CAS  Google Scholar 

  84. Murphy LC, Dotzlaw H (1989) Variant estrogen receptor mRNA species in human breast cancer biopsy samples. Mol Endocrinol 3:687–693.

    PubMed  CAS  Google Scholar 

  85. Dotzlaw H, Alkhalaf M, Murphy LC (1992) Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol 6:773–785.

    PubMed  CAS  Google Scholar 

  86. Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SAW (1995) Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res 1:155–159.

    PubMed  CAS  Google Scholar 

  87. Wang Y, Miksicek RJ (1991) Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 5:1707–1715.

    PubMed  CAS  Google Scholar 

  88. Fuqua SAW, Fitzgerald SG, Allred DC, Elledge RM, Nawaz Z, McDonnel D, O’Malley BW, Greene GL, McGuire WL (1992) Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52:483–486.

    PubMed  CAS  Google Scholar 

  89. Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnel DP, Nawaz Z, O’Malley BW, McGuire WL (1991) Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51:105–109.

    PubMed  CAS  Google Scholar 

  90. Koehorst SGA, Cox JJ, Donker GH, da Silva SL, Burbach JPH, Thijssen JHH, Blankenstein MA (1994) Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningiomas. Mol Cell Endocrinol 101:237–245.

    PubMed  CAS  Google Scholar 

  91. Jiang S-Y, Langan-Fahey SM, Stella AL, McCague R, Jordan VC (1992) Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative human breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 6:2167–2174.

    PubMed  CAS  Google Scholar 

  92. Aronica SM, Katzenellenbogen BS (1993) Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7:743–752.

    PubMed  CAS  Google Scholar 

  93. Krishnaraju K, Murugesan K, Vij U, Kapur BML, Farooq A (1991) Calmodulin levels in oestrogen receptor positive and negative human breast tumours. Br J Cancer 346–347.

    Google Scholar 

  94. Greenberg DA, Carpenter CL, Messing RO (1987) Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 47:70–74.

    PubMed  CAS  Google Scholar 

  95. O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB (1986) Triphenylethylenes: A new class of protein kinase C inhibitors. J Natl Cancer Inst 76:1243–1246.

    PubMed  Google Scholar 

  96. O’Brian CA, Housey GM, Weinstein IB (1988) Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 48:3626–3629.

    PubMed  Google Scholar 

  97. Fabian C, Sternson L, Barnet M (1980) Clinical pharmacology of tamoxifen in patients with breast cancer: Comparison of traditional and loading dose schedules. Cancer Treat Rep 64:765–773.

    PubMed  CAS  Google Scholar 

  98. Custodio JBA, Almeida LM, Madeira VMC (1993) The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes. Biochim Biophys Acta 123–129.

    Google Scholar 

  99. Katzenellenbogen BS, Miller AM, Mullick A, Sheen YY (1985) Antiestrogen action in breast cancer cells: Modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res Treat 5:231–243.

    PubMed  CAS  Google Scholar 

  100. Wilmer EN (1961) Steroids and cell surfaces. Biol Rev 36:368–398.

    Google Scholar 

  101. Lenaz G, Curatola G, Mazzanti L, Parenti-Castelli G (1978) Biophysical studies on agents affecting the state of membrane lipids: Biochemical and pharmacological implications. Mol Cell Biochem 22:3–32.

    PubMed  CAS  Google Scholar 

  102. Freter CE, Lippman ME, Cheville A, Zinn S, Gelmann EP (1988) Alterations in phosphoinositide metabolism associated with 17β-estradiol and growth factor treatment of MCF-7 breast cancer cells. Mol Endocrinol 2:159–166.

    PubMed  CAS  Google Scholar 

  103. Nicholson RI, Gee JMW, Anderson E, Dowsett M, DeFriend D, Howell A, Robertson JFR, Blarney RW, Baum M, Saunders C, Walton P, Wakeling AE (1993) Phase I study of a new pure antiestrogen ICI 182,780 in women with primary breast cancer: Immunohistochemical analysis. Breast Cancer Res Treat 27:135.

    Google Scholar 

  104. Brünner N, Boysen B, Kiilgaard TL, Frandsen TL, Jirus S, Clarke R (1993) Resistance to 40H-Tamoxifen does not confer resistance to the steroidal antiestrogen ICI 182,780, while acquired resistance to ICI 182,780 results in cross resistance to 40H-TAM. Breast Cancer Res Treat 27:135.

    Google Scholar 

  105. Day RS (1986) Treatment sequencing, assymetry and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 46:3876–3885.

    PubMed  CAS  Google Scholar 

  106. Norton L, Day R (1991) Potential innovations in scheduling cancer chemotherapy. In VT DeVita, S Hellman, SA Rosenberg, eds. Important Advances in Oncology. Philadelphia: JB Lippincott, pp 57–73.

    Google Scholar 

  107. Bates SE, Davidson NE, Valverius EM, Dickson RB, Freter CE, Tarn JP, Kudlow JE, Lippman ME, Salomon S (1988) Expression of transforming growth factor-α and its mRNA in human breast cancer: Its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543–545.

    PubMed  CAS  Google Scholar 

  108. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Derynck R, Dickson RB (1987) Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–428.

    PubMed  CAS  Google Scholar 

  109. Clarke R, Brünner N (1995) Cross resistance and molecular mechanisms in antiestrogen resistance. Endocr Related Cancer 2:59–72.

    CAS  Google Scholar 

  110. Clarke R, Skaar T, Baumann K, Leonessa K, James MP, Lippman J, Thompson EW, Freter C, Brünner N (1994) Hormonal carcinogenesis in breast cancer: Cellular and molecular studies of malignant progression. Breast Cancer Res Treat 31:237–248.

    PubMed  CAS  Google Scholar 

  111. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG (1990) Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mdiated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883–6887.

    PubMed  CAS  Google Scholar 

  112. Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037–4041.

    PubMed  CAS  Google Scholar 

  113. Murray A, Hunt T (1993) The Cell Cycle. New York: WH Freeman.

    Google Scholar 

  114. Tzukerman M, Zhang X-K, Herman T, Wills KN, Graupner G, Pfahl M (1990) The human estrogen receptor has transcriptional activator and repressor functions in the absence of a ligand. New Biologist 2:613–620.

    PubMed  CAS  Google Scholar 

  115. Xing H, Haase S, Shapiro DJ (1994) Antiestrogens activate an estrogen receptor mutant exhibiting enhanced binding to the estrogen response element. Biochem Biophys Res Commun 202:888–895.

    PubMed  CAS  Google Scholar 

  116. Curtis SW, Korach KS (1991) Uterine estrogen receptor-DNA complexes: Effects of different ERE sequences, ligands, and receptor forms. Mol Endocrinol 5:959–966.

    PubMed  CAS  Google Scholar 

  117. Dana SL, Hoener PA, Wheeler DA, Lawrence CB, McDonnell DP (1994) Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. Mol Endocrinol 8:1193–1207.

    PubMed  CAS  Google Scholar 

  118. Yoshinaga SK, Peterson CL, Herskowitz I, Yamamoto KR (1992) Roles of SWI1, SWI2 and SWI3 proteins for transcriptional enhancement by steroid receptors. Science 258:1596–1604.

    Google Scholar 

  119. Landel CC, Kushner PJ, Greene GL (1994) The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol 8:1407–1419.

    PubMed  CAS  Google Scholar 

  120. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M (1994) Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 264:1455–1458.

    PubMed  CAS  Google Scholar 

  121. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659–669.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Todd Skaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabio Leonessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brenda Brankin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mattie James
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nils Brünner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marc E. Lippman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

  2. Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

  3. Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 679 Hoes Lane, Room 242, Piscataway, NJ, 08854, USA

    William N. Hait M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Clarke, R. et al. (1996). Acquisition of an Antiestrogen-Resistant Phenotype in Breast Cancer: Role of Cellular and Molecular Mechanisms. In: Hait, W.N. (eds) Drug Resistance. Cancer Treatment and Research, vol 87. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1267-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1267-3_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8540-3

  • Online ISBN: 978-1-4613-1267-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation